- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
March 26, 2024Ronald Schutz, Brendan Johnson Named to Forbes Top 200 Lawyers in the United States
-
March 21, 2024Robins Kaplan Firm Members Appointed to Law360 Editorial Boards
-
March 20, 2024Brandon Vaughn Inducted into The International Society of Barristers
-
April 5, 2024Mass Torts Made Perfect
-
April 17, 2024American Antitrust Institute Virtual CLE Lunch & Learn
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
March 2024Do We Have to Share That Information? Attorney-Client Privilege in the Multi-Entity Context
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Winter 2016
Case Name | Date Filed | Judge | Drug | Patent No(s). |
---|---|---|---|---|
Mylan Pharms. Inc. v. Shire Labs., Inc., IPR2017-00011 (PTAB) | Oct. 4, 2016 | N/A | Adderall XR® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) | RE41,148 |
Amgen Inc. v. Ajanta Pharma Ltd., 16-0899 (D. Del.) | Oct. 5, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
Amgen Inc. v. Dr. Reddy’s Labs., Ltd., 16-0900 (D. Del.) | Oct. 5, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
UCB, Inc. v. Zydus Pharms. (USA) Inc., 16-0903 (D. Del.) | Oct. 6, 2016 | Hon. Leonard P. Stark | Vimpat® (lacosamide for injection) | RE38,551 |
Astellas Pharma Inc. v. Actavis Elizabeth LLC, 16-0905 (D. Del.) | Oct. 6, 2016 | Hon. Sue L. Robinson | Myrbetriq® (mirabegron extended-release tablets) | 6,346,532, 7,342,117, 7,982,049, 8,835,474, RE44,872 |
Alcon Research, Ltd. v. Apotex Inc., 16-0906 (D. Del.) | Oct. 6, 2016 | Hon. Sue L. Robinson | Pazeo® (olopatadine hydrochloride ophthalmic solution) | 8,791,154 |
Astellas Pharma Inc. v. Lupin Ltd., 16-0908 (D. Del.) | Oct. 7, 2016 | Hon. Sue L. Robinson | Myrbetriq® (mirabegron extended-release tablets) | 7,342,117, 7,982,049, 8,835,474, RE44,872 |
Alza Corp. v. Amneal Pharms. of New York, LLC, 16-0914 (D. Del.) | Oct. 7, 2016 | Hon. Richard G. Andrews | Concerta® (methylphenidate hydrochloride tablets) | 8,163,798, 9,144,549 |
Forest Labs., LLC v. Amerigen Pharms., Inc., 16-0917 (D. Del.) | Oct. 7, 2016 | Hon. Leonard P. Stark | Namzaric® (memantine hydrochloride / donepezil hydrochloride extended-release capsules) | 8,039,009, 8,058,291, 8,168,209, 8,173,708, 8,283,379, 8,293,794, 8,329,752, 8,338,485, 8,338,486, 8,362,085, 8,580,858, 8,598,233 |
Alcon Pharms. Ltd. v. Dr. Reddy’s Labs., Inc., 16-6775 (D.N.J.) | Oct. 7, 2016 | Hon. Peter G. Sheridan | Ciprodex® (ciprofloxacin / dexamethasone otic suspension) | 9,402,805 |
Mylan Pharms. Inc. v. Bayer Intellectual Property GmbH, IPR2017-00041 (PTAB) | Oct. 7, 2016 | N/A | Xarelto® (rivaroxaban tablets) | 7,157,456 |
Mylan Pharms. Inc. v. Bayer Intellectual Property GmbH, IPR2017-00042 (PTAB) | Oct. 7, 2016 | N/A | Xarelto® (rivaroxaban tablets) | 7,585,860 |
Mylan Pharms. Inc. v. Bayer Intellectual Property GmbH, IPR2017-00043 (PTAB) | Oct. 7, 2016 | N/A | Xarelto® (rivaroxaban tablets) | 7,592,339 |
Astellas Pharma Inc. v. Zydus Pharms. (USA), Inc., 16-0924 (D. Del.) | Oct. 11, 2016 | Hon. Sue L. Robinson | Myrbetriq® (mirabegron extended-release tablets) | 7,342,117, 7,982,049, 8,835,474, RE44,872 |
Amgen Inc. v. Amneal Pharms. LLC, 16-0925 (D. Del.) | Oct. 11, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
Amgen Inc. v. Apotex Inc., 16-0926 (D. Del.) | Oct. 11, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
Amgen Inc. v. Breckenridge Pharm. Inc., 16-0927 (D. Del.) | Oct. 11, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
Amgen Inc. v. Hetero USA Inc., 16-0928 (D. Del.) | Oct. 11, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
Astellas Pharma Inc. v. Windlas Healthcare, Pvt. Ltd., 16-0930 (D. Del.) | Oct. 12, 2016 | Hon. Sue L. Robinson | Myrbetriq® (mirabegron extended-release tablets) | 7,342,117, 7,982,049, 8,835,474, RE44,872 |
Astellas Pharma Inc. v. Aurobindo Pharma Ltd., 16-0942 (D. Del.) | Oct. 13, 2016 | Hon. Sue L. Robinson | Myrbetriq® (mirabegron extended-release tablets) | 7,342,117, 7,982,049, 8,835,474, RE44,872 |
Astellas Pharma Inc. v. Prinston Pharm. Inc., 16-0943 (D. Del.) | Oct. 13, 2016 | Hon. Sue L. Robinson | Myrbetriq® (mirabegron extended-release tablets) | 7,342,117, 7,982,049, 8,835,474, RE44,872 |
Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution, Inc., 16-0944 (D. Del.) | Oct. 13, 2016 | Hon. Gregory M. Sleet | Inomax® (nitric oxide for inhalation) | 9,408,993 |
Astellas Pharma Inc. v. Sandoz Inc., 16-0952 (D. Del.) | Oct. 14, 2016 | Hon. Sue L. Robinson | Myrbetriq® (mirabegron extended-release tablets) | 7,342,117, 7,982,049, 8,835,474, RE44,872 |
AstraZeneca AB v. Glenmark Pharms. Ltd., 16-7330 (D.N.J.) | Oct. 14, 2016 | Hon. Mary L. Cooper | Nexium® 24HR (esomeprazole magnesium delayed-release capsules) | 6,369,085, 7,411,070, 8,466,175 |
Otsuka Pharm. Co., Ltd. v. Stason Indus. Corp., 16-7346 (D.N.J.) | Oct. 14, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,359,302 |
Astellas Pharma Inc. v. Sawai Pharm. Co., Ltd., 16-0954 (D. Del.) | Oct. 17, 2016 | Hon. Sue L. Robinson | Myrbetriq® (mirabegron extended-release tablets) | 6,346,532, 7,342,117, 7,982,049, 8,835,474, RE44,872 |
Celgene Corp. v. Dr. Reddy’s Labs., Ltd., 16-7704 (D.N.J.) | Oct. 20, 2016 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,465,800, 7,855,217, 7,968,569, 8,530,498, 8,648,095, 9,101,621, 9,101,622 |
Astellas Pharma Inc. v. Apotex Inc., 16-0976 (D. Del.) | Oct. 21, 2016 | Hon. Sue L. Robinson | Myrbetriq® (mirabegron extended-release tablets) | 7,342,117, 7,982,049, 8,835,474, RE44,872 |
Otsuka Pharm. Co., Ltd. v. Zydus Pharms. USA Inc., 16-7705 (D.N.J.) | Oct. 21, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,359,302 |
Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 16-7721 (D.N.J.) | Oct. 21, 2016 | Hon. Jose L. Linares | Narcan® (naloxone hydrochloride nasal spray) | 9,211,253 |
Takeda Pharms. U.S.A., Inc. v. Mylan Pharms. Inc., 16-0987 (D. Del.) | Oct. 24, 2016 | Hon. Sue L. Robinson | Colcrys® (colchicine tablets) | 7,906,519, 7,935,731, 8,093,298, 7,964,648, 8,093,297, 7,619,004, 7,601,758, 7,820,681, 7,915,269, 7,964,647, 7,981,938, 8,093,296, 8,097,655, 8,415,395, 8,415,396, 8,440,721, 8,440,722 |
Onyx Therapeutics, Inc. v. Cipla Ltd., 16-0988 (D. Del.) | Oct. 24, 2016 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,417,042, 7,232,818, 7,491,704, 7,737,112, 8,129,346, 8,207,125, 8,207,126, 8,207,127, 8,207,297 |
Takeda Pharms. U.S.A., Inc. v. Mylan Pharms. Inc., 16-0202 (N.D.W.V.) | Oct. 25, 2016 | Hon. Irene M. Keeley | Colcrys® (colchicine tablets) | 7,906,519, 7,935,731, 8,093,298, 7,964,648, 8,093,297, 7,619,004, 7,601,758, 7,820,681, 7,915,269, 7,964,647, 7,981,938, 8,093,296, 8,097,655, 8,415,395, 8,415,396, 8,440,721, 8,440,722 |
Millennium Pharms., Inc. v. Hospira, Inc., 16-0998 (D. Del.) | Oct. 26, 2016 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) | 6,713,446 |
Onyx Therapeutics, Inc. v. MSN Pharms., Inc., 16-0999 (D. Del.) | Oct. 26, 2016 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,737,112 |
Onyx Therapeutics, Inc. v. Sagent Pharms., Inc., 16-1000 (D. Del.) | Oct. 26, 2016 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,417,042, 7,232,818, 7,491,704, 7,737,112, 8,129,346, 8,207,125, 8,207,126, 8,207,127, 8,207,297 |
Eli Lilly and Co. v. Cipla Ltd., 16-2911 (S.D. Ind.) | Oct. 26, 2016 | Hon. Richard L. Young | Axiron® (testosterone metered transdermal solution) | 8,435,944, 8,993,520, 9,180,194 |
Onyx Therapeutics, Inc. v. Breckenridge Pharm., Inc., 16-1001 (D. Del.) | Oct. 27, 2016 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,417,042, 7,232,818, 7,491,704, 7,737,112, 8,129,346, 8,207,125, 8,207,126, 8,207,127, 8,207,297 |
Galderma Labs., L.P. v. Sun Pharm. Indus. Ltd., 16-1003 (D. Del.) | Oct. 27, 2016 | Hon. Leonard P. Stark | Oracea® (doxycycline tablets) | 7,211,267, 7,232,572, 8,603,506, 7,749,532, 8,206,740, 8,394,405, 8,394,406, 8,470,364, 8,709,478, 9,241,946 |
Eli Lilly and Co. v. Cipla Ltd., 16-1005 (D. Del.) | Oct. 28, 2016 | Hon. Sue L. Robinson | Axiron® (testosterone metered transdermal solution) | 8,435,944, 8,993,520, 9,180,194 |
Eli Lilly and Co. v. Accord Healthcare, Inc., 16-1352 (E.D. Va.) | Oct. 28, 2016 | Hon. Anthony J. Trenga | Cialis® (tadalafil tablets) | 6,943,166 |
Indivior Inc. v. Actavis Labs. UT, Inc., 16-1009 (D. Del.) | Oct. 31, 2016 | Hon. Richard G. Andrews | Suboxone® (buprenorphine / naloxone sublingual film) | 8,475,832, 8,017,150, 8,603,514 |
Otsuka Pharm. Co., Ltd. v. Indoco Remedies Ltd., 16-8085 (D.N.J.) | Oct. 31, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,359,302, 9,387,182 |
Amarin Pharma, Inc. v. Roxane Labs., Inc., 16-2525 (D. Nev.) | Oct. 31, 2016 | Hon. Miranda M. Du | Vascepa® (icosapent ethyl capsules) | 8,293,728, 8,318,715, 8,357,677, 8,367,652, 8,377,920, 8,399,446, 8,415,335, 8,426,399, 8,431,560, 8,440,650, 8,518,929, 8,524,698, 8,546,372, 8,617,594 |
Onyx Therapeutics, Inc. v. Dr. Reddy’s Labs., Inc., 16-1011 (D. Del.) | Nov. 1, 2016 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,737,112 |
Onyx Therapeutics, Inc. v. Fresenius Kabi USA, LLC, 16-1012 (D. Del.) | Nov. 1, 2016 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,417,042, 7,232,818, 7,491,704, 7,737,112, 8,129,346, 8,207,125, 8,207,126, 8,207,127, 8,207,297 |
Onyx Therapeutics, Inc. v. Qilu Pharma, Inc., 16-1013 (D. Del.) | Nov. 1, 2016 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,737,112 |
Eli Lilly and Co. v. Fresenius Kabi USA, LLC, 16-2960 (S.D. Ind.) | Nov. 1, 2016 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
Acrux DDS Pty Ltd. v. Kaken Pharm. Co., Ltd., IPR2017-00190 (PTAB) | Nov. 2, 2016 | N/A | Jublia® (efinaconazole topical solution) | 7,214,506 |
Mylan Pharms. Inc. v. Yeda Research & Development Co., Ltd., IPR2017-00195 (PTAB) | Nov. 2, 2016 | N/A | Copaxone® (glatiramer acetate injection) | 9,155,776 |
UCB, Inc. v. Zydus Worldwide DMCC, 16-1023 (D. Del.) | Nov. 3, 2016 | Hon. Sue L. Robinson | Neupro® (rotigotine transdermal system) | 8,246,979, 8,246,980, 8,617,591, 6,884,434 |
Medicis Pharm. Corp. v. Dr. Reddy’s Labs., Ltd., 16-8282 (D.N.J.) | Nov. 4, 2016 | Hon. Brian R. Martinotti | Solodyn® (minocycline hydrochloride extended-release tablets) | 5,908,838, 7,790,705, 7,919,483, 8,252,776, 8,268,804, 8,722,650 |
Otsuka Pharm. Co., Ltd. v. Zhejiang Huahai Pharm. Co., Ltd., 16-8284 (D.N.J.) | Nov. 4, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,359,302, 9,387,182 |
Amarin Pharma, Inc. v. Dr. Reddy’s Labs., Inc., 16-2562 (D. Nev.) | Nov. 4, 2016 | Hon. Robert C. Jones | Vascepa® (icosapent ethyl capsules) | 8,293,728, 8,318,715, 8,357,677, 8,367,652, 8,377,920, 8,399,446, 8,415,335, 8,426,399, 8,431,560, 8,440,650, 8,518,929, 8,524,698, 8,546,372, 8,617,594 |
Mylan Technologies, Inc. v. Monosol Rx, LLC, IPR2017-00200 (PTAB) | Nov. 4, 2016 | N/A | Suboxone® (buprenorphine / naloxone sublingual film) | 8,603,514 |
Mylan Pharms. Inc. v. Qualicaps Co.Ltd, IPR2017-00203 (PTAB) | Nov. 4, 2016 | N/A | Delzicol® (mesalamine delayed-release capsule) | 6,649,180 |
Onyx Therapeutics, Inc. v. InnoPharma, Inc., 16-1036 (D. Del.) | Nov. 8, 2016 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,417,042, 7,737,112, 8,207,297 |
Onyx Therapeutics, Inc. v. Apotex Inc., 16-1039 (D. Del.) | Nov. 8, 2016 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,737,112 |
Forest Labs., LLC v. Apotex Corp., 16-1045 (D. Del.) | Nov. 10, 2016 | Hon. Leonard P. Stark | Namzaric® (memantine hydrochloride / donepezil hydrochloride extended-release capsules) | 8,039,009, 8,058,291, 8,338,485, 8,338,486, 8,580,858 |
Alcon Research, Ltd. v. Akorn, Inc., 16-3092 (S.D. Ind.) | Nov. 11, 2016 | Hon. Jane Magnus-Stinson | Pataday® (olopatadine hydrochloride ophthalmic solution) | 6,995,186, 7,402,609 |
The Medicines Co. v. Akorn, Inc., 16-8546 (D.N.J.) | Nov. 15, 2016 | Hon. Peter G. Sheridan | Angiomax® (bivaluirudin for injection) | 7,582,727, 7,598,343 |
United Therapeutics Corp. v. Par Sterile Products, LLC, 16-8548 (D.N.J.) | Nov. 16, 2016 | Hon. Peter G. Sheridan | Remodulin® (treprostinil sodium for injection) | 8,497,393, 9,199,908, 7,999,007, 8,653,137, 8,658,694 |
United Therapeutics Corp. v. Par Sterile Products, LLC, 16-1066 (D. Del.) | Nov. 17, 2016 | Hon. Sue L. Robinson | Remodulin® (treprostinil sodium for injection) | 8,497,393, 9,199,908, 7,999,007, 8,653,137, 8,658,694 |
Apotex Inc. v. Alcon Research, Ltd., 16-3145 (S.D. Ind.) | Nov. 17, 2016 | Hon. William T. Lawrence | Pataday® (olopatadine hydrochloride ophthalmic solution) | 6,995,186, 7,402,609 |
Alkermes Pharma Ireland Ltd. v. Otsuka Pharm. Co., Ltd., IPR2017-00287 (PTAB) | Nov. 17, 2016 | N/A | Abilify® (aripiprazole tablets) | 9,125,939 |
Aptalis Pharma Canada ULC v. Par Pharm., Inc., 16-1069 (D. Del.) | Nov. 18, 2016 | Hon. Sue L. Robinson | Pylera® (bismuth subcitrate potassium / metronidazole / tetracycline hydrochloride capsules) | 6,350,468 |
Amarin Pharma, Inc. v. Teva Pharms. USA, Inc., 16-2658 (D. Nev.) | Nov. 18, 2016 | Hon. Miranda M. Du | Vascepa® (icosapent ethyl capsules) | 8,293,728, 8,318,715, 8,357,677, 8,367,652, 8,377,920, 8,399,446, 8,415,335, 8,426,399, 8,431,560, 8,440,650, 8,518,929, 8,524,698, 8,546,372, 8,617,594 |
Mylan Pharms. Inc. v. Icos Corp., IPR2017-00323 (PTAB) | Nov. 22, 2016 | N/A | Cialis® (tadalafil tablets) | 6,943,166 |
Merck, Sharp & Dohme Corp. v. Strides Pharma Inc., 16-8850 (D.N.J.) | Nov. 29, 2016 | Hon. Brian R. Martinotti | Sustiva® (efavirenz tablets) | 6,639,071, 6,939,964, 6,673,372 |
Forest Labs., LLC v. Teva Pharms. USA, Inc., 16-1114 (D. Del.) | Nov. 30, 2016 | Hon. Richard G. Andrews | Linzess® (linaclotide capsules) | 7,304,036, 7,371,727, 7,704,947, 7,745,409, 8,080,526, 8,110,553, 8,748,573, 8,802,628, 8,933,030 |
Eli Lilly and Co. v. Apotex, Inc., 16-0941 (E.D. Va.) | Nov. 30, 2016 | Hon. M. Hannah Lauck | Cialis® (tadalafil tablets) | 6,943,166 |
Mallinckrodt IP v. Mylan Labs. Ltd., 16-1115 (D. Del.) | Dec. 1, 2016 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) | 6,028,222, 6,992,218 |
Malinckrodt IP v. Innopharma Licensing LLC, 16-1116 (D. Del.) | Dec. 1, 2016 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) | 9,399,012 |
Astellas Pharma Inc. v. Actavis Labs. FL, Inc., 16-1120 (D. Del.) | Dec. 2, 2016 | Hon. Gregory M. Sleet | Xtandi® (enzalutamide capsules) | 7,709,517, 8,183,274, 9,126,941 |
Merck, Sharp & Dohme Corp. v. Aurobindo Pharma Ltd., 16-9033 (D.N.J.) | Dec. 6, 2016 | Hon. Brian R. Martinotti | Sustiva® (efavirenz tablets) | 6,639,071, 6,939,964, 6,673,372 |
Horizon Pharma, Inc. v. Dr. Reddy’s Labs. Inc., 16-9035 (D.N.J.) | Dec. 6, 2016 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 9,393,208 |
Valeant Pharms. Int’l, Inc. v. Actavis Labs. FL, Inc., 16-9038 (D.N.J.) | Dec. 6, 2016 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide tablets) | 8,420,663, 8,524,276, 8,956,651, 9,180,125, 9,314,461 |
MonoSol Rx, LLC v. Icos Corp., IPR2017-00412 (PTAB) | Dec. 6, 2016 | N/A | Cialis® (tadalafil tablets) | 6,943,166 |
Orexo AB v. Actavis Elizabeth LLC, 16-1138 (D. Del.) | Dec. 7, 2016 | Hon. Sue L. Robinson | Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride dihydrate sublingual tablets) | 9,439,900 |
Orexo AB v. Actavis Elizabeth LLC, 16-1139 (D. Del.) | Dec. 7, 2016 | Hon. Sue L. Robinson | Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride dihydrate sublingual tablets) | 9,439,900 |
Abraxis Bioscience, LLC v. Cipla Ltd., 16-9074 (D.N.J.) | Dec. 7, 2016 | Hon. John Michael Vazquez | Abraxane® (paclitaxel protein-bound particles for injectable suspension) | 7,820,788, 7,923,536, 8,138,229, 8,853,260 |
Astellas Pharma Inc. v. Apotex Inc., 16-1166 (D. Del.) | Dec. 9, 2016 | Hon. Gregory M. Sleet | Xtandi® (enzalutamide capsules) | 7,709,517, 8,183,274, 9,126,941 |
Astellas Pharma Inc. v. Zydus Pharms. (USA) Inc., 16-1167 (D. Del.) | Dec. 9, 2016 | Hon. Gregory M. Sleet | Xtandi® (enzalutamide capsules) | 7,709,517, 8,183,274, 9,126,941 |
Apicore US LLC v. Pfizer Inc., 16-1174 (D. Del.) | Dec. 12, 2016 | Hon. Sue L. Robinson | Tikosyn® (dofetilide capsules) | 6,124,363 |
Eli Lilly and Co. v. Ajanta Pharma, Ltd., 16-0714 (E.D. Va.) | Dec. 13, 2016 | Hon. Mark S. Davis | Cialis® (tadalafil tablets) | 6,943,166 |
Bayer Healthcare LLC v. Teva Pharms. USA, Inc., 16-1220 (D. Del.) | Dec. 16, 2016 | Hon. Leonard P. Stark | Nexavar (sorafenib tosylate tablets) | 8,877,933 |
Bayer Healthcare LLC v. Teva Pharms. USA, Inc., 16-1221 (D. Del.) | Dec. 16, 2016 | Hon. Leonard P. Stark | Stivarga® (regorafenib tablets) | 7,351,834, 8,637,553, 8,680,124, 9,458,107 |
Bayer Healthcare LLC v. Apotex, Inc., 16-1222 (D. Del.) | Dec. 16, 2016 | Hon. Leonard P. Stark | Stivarga® (regorafenib tablets) | 8,637,553 |
Millennium Pharms., Inc. v. MSN Labs. Private Ltd., 16-1255 (D. Del.) | Dec. 19, 2016 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) | 6,713,446, 6,958,319 |
Teva Pharms. USA, Inc. v. Dr. Reddy’s Labs., Ltd., 16-1267 (D. Del.) | Dec. 19, 2016 | Hon. Gregory M. Sleet | Copaxone® (glatiramer acetate injection) | 9,402,874 |
Impax Labs., Inc. v. Actavis Labs. FL, Inc., 16-9416 (D.N.J.) | Dec. 20, 2016 | Hon. Stanley R. Chesler | Rytary® (levodopa / carbidopa extended-release capsules) | 9,463,246 |
Eli Lilly and Co. v. Hospira, Inc., 16-3460 (S.D. Ind.) | Dec. 21, 2016 | Hon. Sarah Evans Barker | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
Sanofi-Aventis U.S. LLC v. Watson Labs., Inc., 16-1298 (D. Del.) | Dec. 22, 2016 | Hon. Gregory M. Sleet | Aubagio® (teriflunomide tablets) | 6,794,410, 9,186,346 |
Sanofi-Aventis U.S. LLC v. Aurobindo Pharma USA, Inc., 16-1299 (D. Del.) | Dec. 22, 2016 | Hon. Gregory M. Sleet | Aubagio® (teriflunomide tablets) | 6,794,410, 9,186,346 |
Sanofi-Aventis U.S. LLC v. Alvogen Pine Brook LLC, 16-1300 (D. Del.) | Dec. 22, 2016 | Hon. Gregory M. Sleet | Aubagio® (teriflunomide tablets) | 6,794,410, 9,186,346 |
Biodelivery Sciences Int’l, Inc. v. Teva Pharms. USA, Inc., 16-1303 (D. Del.) | Dec. 22, 2016 | Hon. Gregory M. Sleet | Belbuca® (buprenorphine buccal film) | 7,579,019, 8,147,866 |
Allergan, Inc. v. Deva Holding A.S., 16-1447 (E.D. Tex.) | Dec. 22, 2016 | Hon. Robert W. Schroeder, III | Restasis® (cyclosporine ophthalmic emulsion) | 8,629,111, 8,633,162, 8,642,556, 8,648,048, 8,685,930, 9,248,191 |
Wyeth LLC v. Alembic Pharms., Ltd., 16-1305 (D. Del.) | Dec. 23, 2016 | Hon. Richard G. Andrews | Bosulif® (bosutinib tablets) | 7,417,148, 7,767,678 |
Rhodes Pharms. L.P. v. Indivior Inc., 16-1308 (D. Del.) | Dec. 23, 2016 | Hon. Sue L. Robinson | Suboxone® (buprenorphine / naloxone sublingual film) | 9,370,512 |
Sanofi-Aventis U.S. LLC v. Accord Healthcare, Inc., 16-1311 (D. Del.) | Dec. 27, 2016 | Hon. Gregory M. Sleet | Aubagio® (teriflunomide tablets) | 6,794,410, 9,186,346 |
Sanofi-Aventis U.S. LLC v. Apotex, Inc., 16-1312 (D. Del.) | Dec. 27, 2016 | Hon. Gregory M. Sleet | Aubagio® (teriflunomide tablets) | 6,794,410, 9,186,346 |
Sanofi-Aventis U.S. LLC v. Alembic Pharms. Ltd., 16-1316 (D. Del.) | Dec. 28, 2016 | Hon. Gregory M. Sleet | Aubagio® (teriflunomide tablets) | 6,794,410, 9,186,346 |
Sanofi-Aventis U.S. LLC v. Glenmark Pharms. Inc., USA, 16-1326 (D. Del.) | Dec. 29, 2016 | Hon. Gregory M. Sleet | Aubagio® (teriflunomide tablets) | 6,794,410, 9,186,346 |
AstraZeneca AB v. Cipla Ltd., 16-9583 (D.N.J.) | Dec. 29, 2016 | Hon. Mary L. Cooper | Nexium® 24HR (esomeprazole magnesium delayed-release capsules) | 6,369,085, 7,411,070 |
Sanofi-Aventis U.S. LLC v. Emcure Pharms. Ltd., 16-1330 (D. Del.) | Dec. 30, 2016 | Hon. Gregory M. Sleet | Aubagio® (teriflunomide tablets) | 9,186,346 |
Sanofi-Aventis U.S. LLC v. Torrent Pharma Inc., 16-1333 (D. Del.) | Dec. 30, 2016 | Hon. Gregory M. Sleet | Aubagio® (teriflunomide tablets) | 6,794,410, 9,186,346 |
Otsuka Pharm. Co., Ltd. v. Orchid Pharma Ltd., 16-9603 (D.N.J.) | Dec. 30, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,358,207 |
GENERICally Speaking Winter 2016
Related Professionals
Miles A. Finn, Ph.D.
Counsel
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.